The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack

References

• Xu G, Liu X, Wu W, et al. Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis. 2007;23(2–3):117–120.
   Google Scholar
• Kang K, Park TH, Kim N, et al. Recurrent stroke, myocardial infarction, and major vascular events during the first year after acute ischemic stroke: the multicenter prospective observational study about recurrence and its determinants after acute ischemic stroke I. J Stroke Cerebrovasc Dis. 2016;25(3):656–664.
   Google Scholar
• Mohan KM, Crichton SL, Grieve AP, et al. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2009;80(9):1012–1018.
   Google Scholar
• Coull AJ, Lovett JK, Rothwell PM, et al. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ : British Medical Journal. 2004;328(7435):326.
   Google Scholar
• Mohan KM, Wolfe CDA, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–1494.
   Google Scholar
• Feske SK. Genetic profile–guided therapy for stroke? N Engl J Med. 2021;385(27):2576–2577.
   Google Scholar
• Collaboration AT, Group BMJP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
   Google Scholar
• NICE. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal 210). National Institute for Health and Clinical Excellence. 2010.
   Google Scholar
• The European Stroke Prevention Study (ESPS): principal end-points. Lancet. 1987;330(8572):1351–1354.
   Google Scholar
• Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19.
   Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2. dipyridamole and acetylsalicylic acid in the secondary prevention of stroke1. J Neurol Sci. 1996;143(1–2):1–13.
   Google Scholar
• CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339
   Google Scholar
• Bowry ADK, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960–966.
   Google Scholar
• Leonardi-Bee J, Bath PMW, Bousser M-G, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events. Stroke. 2005;36(1):162–168.
   Google Scholar
• McHutchison C, Blair GW, Appleton JP, et al. Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke. 2020;51(8):2374–2385.
   Google Scholar
• Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215.
   Google Scholar
• Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391(10123):850–859
   Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–217.
   Google Scholar
• Amarenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial. JAMA Neurol. 2021;78(2):177–185.
   Google Scholar
• James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342(jun17 1):d3527.
   Google Scholar
• Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–2944.
   Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631.
   Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43.
   Google Scholar
• Gurbel PA, Jeong Y-H, Tantry US. Personalized antiplatelet therapy: state of the art. JRSM Cardiovasc Dis. 2012;1(6): cvd.2012.012015.
   Google Scholar
• Ventola CL. Pharmacogenomics in clinical practice: reality and expectations. Pharm Ther. 2011;36(7):412.
   Google Scholar
• Fan J, de Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87(1):93–120.
   Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323.
   Google Scholar
• Daly AK. Pharmacogenetics: a general review on progress to date. Br Med Bull. 2017;124(1):65–79.
   Google Scholar
• Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109(2):302–309.
   Google Scholar
• Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022. DOI:10.1002/cpt.2526.
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375.
   Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.
   Google Scholar
• Hulot J-S, Collet J-P, Montalescot G. Genetic substudy of the PLATO trial. Lancet. 2011;377(9766):637–638. author reply.
   Google Scholar
• Pereira NL, Rihal C, Lennon R, et al., Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14(7): 739–750.
   Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   Google Scholar
• Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention. Circulation. 2010;121(1):71–79.
   Google Scholar
• Corbett SJ, Ftouh S, Lewis S, et al. Acute coronary syndromes: summary of updated NICE guidance. BMJ. 2021;372:m4760.
   Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
   Google Scholar
• Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010;8(8):1678–1684.
   Google Scholar
• Carvalho Henriques B, Buchner A, Hu X, et al. Methodology for clinical genotyping of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11(1):1–9.
   Google Scholar
• McDermott JH, Burn J, Donnai D, et al. The rise of point-of-care genetics: how the SARS-CoV-2 pandemic will accelerate adoption of genetic testing in the acute setting. Eur J Hum Genet. 2021;29(6):891–893.
   Google Scholar
• Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized Clinical Trial. JAMA. 2020;324(8):761–771.
   Google Scholar
• Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.
   Google Scholar
• Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25–33.
   Google Scholar
• Qiu L-N, Sun Y, Wang L, et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol. 2015;747:29–35.
   Google Scholar
• Sun W, Li Y, Li J, et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2015;26(6):558–562.
   Google Scholar
• Wang Y, Cai H, Zhou G, et al. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel. J Neurol Sci. 2016;369:216–219.
   Google Scholar
• Chen Y, Zhou Z, Li G, et al. Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients. Acta Pharmacol Sin. 2019;40(6):762–768.
   Google Scholar
• Yi X, Zhou Q, Wang C, et al. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. J Neurol. 2018;265(10):2396–2403.
   Google Scholar
• Lin J, Han Z, Wang C, et al. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. Eur J Clin Pharmacol. 2018;74(9):1131–1140.
   Google Scholar
• Lv H, Yang Z, Wu H, et al. High on-treatment platelet reactivity as predictor of long-term clinical outcomes in stroke patients with antiplatelet agents. Transl Stroke Res. 2021;13(3):391–398.
   Google Scholar
• Lin J, Mo Y, Cai D, et al. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study. Ann Palliat Med. 2021;10(12):12171–12180.
   Google Scholar
• Patel PD, Niu X, Shannon CN, et al. CYP2C19 loss-of-function associated with first-time ischemic stroke in non-surgical asymptomatic carotid artery stenosis during clopidogrel therapy. Transl Stroke Res. 2022;13(1):46–55.
   Google Scholar
• Jia D, Chen Z, Zhang M, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44(6):1717–1719.
   Google Scholar
• Spokoyny I, Barazangi N, Jaramillo V, et al. Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovascular Dis. 2014;23(4):694–698.
   Google Scholar
• Lin Y-J, J-W L, Zhang M-J, et al. The association between CYP2C19 genotype and of in‐stent restenosis among patients with vertebral artery stent treatment. CNS Neurosci Ther. 2014;20(2):125.
   Google Scholar
• Zhang S, Lai X, Li W, et al. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. Thromb Res. 2014;134(6):1272–1277.
   Google Scholar
• Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack. Circulation. 2017;135(1):21–33.
   Google Scholar
• Zhu W-Y, Zhao T, Xiong X-Y, et al. Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia. Sci Rep. 2016;6(1):25478.
   Google Scholar
• X-Q L, Ma N, X-G L, et al. Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting. PLOS ONE. 2016;11(2):e0148891.
   Google Scholar
• Yi X, Wang Y, Lin J, et al. Interaction of CYP2C19, P2Y12, and GPIIIa variants associates with efficacy of clopidogrel and adverse events on patients with ischemic stroke. Clin Appl Thromb Hemost. 2017;23(7):761–768.
   Google Scholar
• Lewis JP, Shuldiner AR. PON1 Q192R variant and clopidogrel efficacy: fact or fiction? Circ Cardiovasc Genet. 2012;5(2):153–155.
   Google Scholar
• Jeong T-D, Kim SM, Kim HJ, et al. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. J Stroke Cerebrovasc Dis. 2015;24(2):440–446.
   Google Scholar
• Li Y, Tang H-L, Y-F H, et al. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10:199–206.
   Google Scholar
• Wang Y-J, Z-X L, H-Q G, et al. China stroke statistics 2019: a report from the national center for healthcare quality management in neurological diseases, China national clinical research center for neurological diseases, the Chinese stroke association, National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol [Internet]. 2020;5. [cited 2022 Jan 9]. Available from: https://svn.bmj.com/content/5/3/211.
   Google Scholar
• GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379: 2429–2437.
   Google Scholar
• Wang Y, Meng X, Wang A, et al., Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27): 2520–2530. .
   Google Scholar
• Wang Y, Johnston C, Bath PM, et al. Clopidogrel with aspirin in high-risk patients with acute non-disabling cerebrovascular events II (CHANCE-2): rationale and design of a multicentre randomised trial. Stroke Vasc Neurol. 2021;6(2):280–285.
   Google Scholar
• Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ. 2019;365:l2211.
   Google Scholar
• Han Y, H-H L, Liu X, et al. Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther. 2015;21(9):692–697.
   Google Scholar
• Fang L, Zhao Y, Wang N, et al. Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic han chinese from fujian. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015;32(6):871–876.
   Google Scholar
• Yi X, Lin J, Wang Y, et al. Association of cytochrome P450 genetic variants with clopidogrel resistance and outcomes in acute ischemic stroke. J Atheroscler Thromb. 2016;23(10):1188–1200.
   Google Scholar
• Cai Z, Cai D, Wang R, et al. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack. Sci Rep. 2021;11(1):7383.
   Google Scholar
• Hoh BL, Gong Y, McDonough CW, et al. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg. 2016;124(6):1746–1751.
   Google Scholar
• Tornio A, Flynn R, Morant S, et al. Investigating real-world clopidogrel pharmacogenetics in stroke using a bioresource linked to electronic medical records. Clin Pharmacol Ther. 2018;103(2):281–286.
   Google Scholar
• Patel PD, Vimalathas P, Niu X, et al. CYP2C19 loss-of-function is associated with increased risk of ischemic stroke after transient ischemic attack in intracranial atherosclerotic disease. J Stroke Cerebrovasc Dis. 2021;30(2):105464.
   Google Scholar
• Pilling LC, Türkmen D, Fullalove H, et al. Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study. BMJ Open. 2021;11:e053905.
   Google Scholar
• SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–825.
   Google Scholar
• Benavente OR, White CL, Pearce L, et al. The secondary prevention of small subcortical strokes (SPS3) study. Int J Stroke. 2011;6(2):164–175.
   Google Scholar
• McDonough CW, McClure LA, Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc. 2015;4(6):e001652.
   Google Scholar
• Wang Y, Zhao X, Lin J, et al., Association Between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(1): 70–78.
   Google Scholar
• Meschia JF, Walton RL, Farrugia LP, et al., Efficacy of clopidogrel for prevention of stroke based on CYP2C19 allele status in the POINT trial. Stroke. 2020;51(7): 2058–2065.
   Google Scholar
• Edem E, Kirdök AH, Kınay AO, et al. Does “smoker’s paradox” exist in clopidogrel-treated turkish patients with acute coronary syndrome. Platelets. 2016;27(3):240–244.
   Google Scholar
• Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62(6):505–512.
   Google Scholar
• Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917–1921.
   Google Scholar
• Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009;53(15):1273–1278.
   Google Scholar
• Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA. 2012;307(23):2495–2496.
   Google Scholar
• Ovbiagele B, Wang J, Claiborne JS, et al. Does smoking status influence the effect of clopidogrel on secondary stroke prevention? (S31.005). Neurology [Internet]. 2016;86. [cited 2022 Jan 11]. Available from: https://n.neurology.org/content/86/16_Supplement/S31.005.
   Google Scholar
• Mok V, Srikanth V, Xiong Y, et al. Race-ethnicity and cerebral small vessel disease–comparison between Chinese and white populations. Int J Stroke. 2014;9(A100):36–42.
   Google Scholar
• Tsai C-F, Thomas B, Sudlow CLM. Epidemiology of stroke and its subtypes in Chinese vs white populations. Neurology. 2013;81(3):264–272.
   Google Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–933.
   Google Scholar
• Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161(3):598–604.
   Google Scholar
• Gurbel PA, Tantry US, Shuldiner AR, et al., Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol. 2010;56(2): 112–116.
   Google Scholar
• van Schaik R. Dutch pharmacogenetic working group guidelines [Internet]. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. [cited 2022 Feb 23]. Available from: https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica/pharmacogenetics-1/pharmacogenetics.
   Google Scholar
• Formea CM, Nicholson WT, Vitek CR. An inter-professional approach to personalized medicine education: one institution’s experience. Per Med. 2015;12(2):129.
   Google Scholar
• Hicks JK, Dunnenberger HM, Gumpper KF, et al. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73(23):1967–1976.
   Google Scholar
• Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020;109(6):1417–1423.
   Google Scholar
• Wilke R, Ramsey L, Johnson S, et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112–117.
   Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.
   Google Scholar
• Hicks J, Bishop J, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134.
   Google Scholar